CeriBell, Inc. (NASDAQ:CBLL) Stock Rated “Moderate Buy” by Sell-Side Brokerages

CeriBell, Inc. (NASDAQ:CBLL) has received an average rating of “Moderate Buy” from the seven brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $27.00.

CBLL has been the topic of a number of recent analyst reports. BTIG Research reissued a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a research report on Friday, September 11th. TD Cowen boosted their target price on CeriBell from $29.00 to $33.00 and gave the company a “buy” rating in a research report on Friday, October 2nd. Barclays raised CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. Canaccord Genuity Group increased their price target on CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Finally, Weiss Ratings lowered CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd.

Insider Buying and Selling

In other CeriBell news, VP David Foehr sold 9,255 shares of the company’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $24.25, for a total value of $224,433.75. Following the transaction, the vice president owned 34,144 shares of the company’s stock, valued at $827,992. This represents a 21.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Joseph Taylor sold 13,095 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $23.40, for a total value of $306,423.00. Following the completion of the sale, the director owned 48,478 shares in the company, valued at approximately $1,134,385.20. The trade was a 21.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 174,905 shares of company stock worth $4,312,995 over the last ninety days. Corporate insiders own 17.70% of the company’s stock.

Hedge Funds Weigh In On CeriBell

A number of large investors have recently bought and sold shares of the business. Squarepoint Ops LLC acquired a new position in shares of CeriBell during the second quarter worth $638,000. Wellington Management Group LLP lifted its holdings in shares of CeriBell by 5.5% during the 2nd quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock valued at $1,706,000 after purchasing an additional 4,572 shares during the last quarter. Formula Growth Ltd. acquired a new stake in shares of CeriBell in the 2nd quarter worth $603,000. Bank of America Corp DE acquired a new stake in shares of CeriBell in the 2nd quarter worth $4,619,000. Finally, PDT Partners LLC acquired a new stake in shares of CeriBell in the 2nd quarter worth $1,026,000.

CeriBell Price Performance

Shares of CeriBell stock traded down $0.14 during trading hours on Tuesday, reaching $25.12. The company’s stock had a trading volume of 27,886 shares, compared to its average volume of 342,903. The firm has a 50 day moving average price of $23.52 and a 200-day moving average price of $20.46. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79. The stock has a market cap of $964.30 million, a P/E ratio of -14.28 and a beta of 0.94. CeriBell has a one year low of $10.85 and a one year high of $25.63.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The business had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. On average, analysts predict that CeriBell will post -1.96 EPS for the current year.

CeriBell Company Profile

CeriBell, Inc develops medical technology designed to make electroencephalography (EEG) more accessible in acute-care settings. Its primary product is the Ceribell Rapid Response EEG system, a portable, point-of-care platform that enables clinicians to record and assess brain activity at the bedside, including when evaluating patients for seizures and status epilepticus.

The Ceribell system combines a simplified EEG headband and recording device with software that supports rapid interpretation.